RxDoctor Payments Data

Luis Bonilla, MD

Family Medicine · San Francisco, CANPI 1629019708

Payments from drug & device makers

$6,421in general payments, 2019–2025

Across 267 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Johnson & Johnson$804
  • AbbVie$696
  • AstraZeneca$597
  • Lilly USA, LLC$590
  • Boehringer Ingelheim$452
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$6,421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,421 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$102,003
Medicare patients
165
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin98$121,939
EliquisApixaban145$113,300
OzempicSemaglutide74$93,090
RybelsusSemaglutide35$77,118
MysolinePrimidone13$61,682
LinzessLinaclotide29$33,102
JanuviaSitagliptin Phosphate19$26,636
CreonLipase/Protease/Amylase25$21,221
XareltoRivaroxaban18$19,917
FarxigaDapagliflozin Propanediol13$16,233
Rosuvastatin Calcium314$11,300
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$6,551
Tresiba Flextouch U-100Insulin Degludec14$5,197
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$4,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,311$170,208109 claims
Boehringer IngelheimJardiance$452$121,93998 claims
PfizerEliquis$427$113,300145 claims
AbbVieLinzess, Creon$696$54,32354 claims
Johnson & JohnsonXarelto$804$19,91718 claims
AstraZenecaFarxiga$597$16,23313 claims
GSKAnoro Ellipta, Trelegy Ellipta$320$15,98533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →